Ondansetron Orally Disintegrating Tablets

Solicitation / RFP / RFQ

This solicitation seeks to establish a national supply source for pharmaceutical products, specifically Ondansetron ODT in various strengths and quantities, to be distributed through the Defense Logistics Agency (DLA) and Department of Veterans Affairs (VA) Pharmaceutical Prime Vendor (PPV) programs. The objective is to ensure product availability, consistency, and obtain volume-based, committed-use pricing for the Department of Defense (DoD), VA, Bureau of Prisons (BoP), and Indian Health Service (IHS) customers.

• Procurement of Ondansetron ODT 4 MG (30 count bottle/box) and Ondansetron ODT 8 MG (10 count and 30 count bottle/box).

• Products must meet FDA current Good Manufacturing Practices (cGMP) standards.

• Specific packaging requirements include child-proof closures, minimum bottle size, and specific label dimensions.

• Bar code labeling at the unit-of-use package level is required, conforming to GS1-128 or HIBCC standards.

• Product registration with RXNorm, First Data Bank, and Medi-Span is mandatory prior to contract performance.

• Offerors must provide information on manufacturing facilities and compliance with FDA regulations.

• Contract type: Firm-fixed-price requirements contract.

• Period of Performance: One base year with four option years, for a maximum of five years.

• Contract Price Effective Date: No more than 60 calendar days after award.

• Contract Performance Date: 45 calendar days after award.

• Payment Structure: Payments will be received from PPV contractors, not directly from the Government.

• Offers must be submitted electronically via the Defense Logistics Agency Internet Bid Board System (DIBBS).

• Submission Deadline: April 22, 2026, 3:00 PM EST.

• Evaluation Criteria: Lowest Price Technically Acceptable (LPTA).

• Proposals will be evaluated on technical acceptability and lowest evaluated aggregate price.

• A reverse auction may be used for price negotiations.

• Offerors must agree to participate in the reverse auction if conducted.

• The acquisition is set aside for small business concerns (NAICS code 325412, size standard 1300).

• Offerors must represent their small business status.

• Offerors are encouraged to approach PPV contractors regarding business-to-business agreements prior to submitting an offer.

• The contract awardee must reach business-to-business agreements with DLA and VA PPV contractors.

• Detailed requirements for product registration, preparation for delivery, labeling, therapeutic equivalence, drug application, manufacturing facilities, and recalls are provided.

Amendment / Modification

This amendment (0003) extends the closing date for the solicitation.

• The opening/closing date has been changed.

• The closing date has been extended to April 22, 2026, at 3:00 PM EST.

• All other terms and conditions of the solicitation remain unchanged.

Amendment / Modification

• The closing date for the solicitation has been extended.

• The original closing date was February 23, 2026, at 3:00 PM EST.

• The new closing date is March 23, 2026, at 3:00 PM EST.

• The opening/closing date specified in the solicitation.

• The deadline for proposal submissions has been extended to March 23, 2026, at 3:00 PM EST.

Amendment / Modification

This amendment (0001) to Solicitation SPE2D225R0018, dated January 22, 2026, is issued to allow for the offering of "Bottles" and/or "Blister Packaging" in response to the solicitation.

• The "Schedule of Items/Pricing Sheet" has been revised to include these new packaging options. Details are provided in the attached "Revised Schedule of Supplies - Ondansetron - Revised.pdf".

• Bidders are now permitted to offer these alternative packaging formats. The solicitation deadline is not extended by this amendment.

Form / Attachment / Pricing Sheet

This document is a "Schedule of Supplies/Services" that details estimated quantities for various pharmaceutical items, specifically Ondansetron ODT, across multiple contract years. It serves as a pricing and quantity reference for potential bidders.

• Item Numbers: 0001, 0002, 0003, each representing a different Ondansetron ODT product (4MG - 30 Count, 8MG - 10 Count, 8MG - 30 Count).
• National Drug Code (NDC): To be specified by the bidder.
• Unit of Measure: One Bottle (BTL) packaged as a Blister Package (BP).
• Estimated Quantities: Quantities are listed for a Base Year and four Option Years for each item.
• Packaging Note: Packaging size is the unit of use and is subject to the Statement of Work's "Preparation for Delivery" requirement.
• Quantity Disclaimer: The quantities specified are estimates only. Reference FAR 52.216-21 for details.

This schedule provides crucial information for bidders to understand the estimated demand and product specifications for Ondansetron ODT. Bidders will use this to prepare their pricing and assess their capacity to meet the estimated quantities over the contract period. The NDC specification and packaging requirements are key details for proposal preparation.

Solicitation / RFP / RFQ

This solicitation is for the procurement of Ondansetron ODT (Orally Disintegrating Tablets) in various strengths and quantities. The Defense Logistics Agency (DLA) Troop Support, Directorate of Medical Materiel, is procuring these pharmaceutical products for the Department of Defense (DoD), Department of Veterans Affairs (VA), Indian Health Service (IHS), and Bureau of Prisons (BoP) through its Pharmaceutical Prime Vendor (PPV) program. The objective is to establish a national supply source to ensure product availability, consistency, and to obtain volume-based, committed use pricing.

• Ondansetron ODT 4 MG Tablet, 30 count bottle (NDC: National Drug Code)

• Ondansetron ODT 8 MG Tablet, 10 count bottle (NDC: National Drug Code)

• Ondansetron ODT 8 MG Tablet, 30 count bottle (NDC: National Drug Code)

• Packaging must be unit of use, with child-proof closures and bottles of a minimum 100cc volume. Bottles must have a cylindrical body and a minimum 5.75" circumference. Labels must be 5.25" x 2" with 0.5" additional space for barcode and expiration date.

• Bar code labeling at the unit-of-use package level is required, conforming to GS1-128 or HIBCC standards.

• Product information must be registered with RXNorm, First Data Bank, and Medi-Span prior to contract performance.

• Offerors must have FDA approval (NDA, ANDA, or Biologic License) for offered drugs, approved no later than the solicitation closing date.

• Manufacturing facilities must have acceptable cGMP status with the FDA.

• Type of Contract: Firm-fixed-price requirements contract.

• Period of Performance: One year base period with four option years, for a maximum term of five years.

• Contract Performance Date: 45 calendar days after award.

• Contract Price Effective Date: No more than 60 calendar days after award.

• Offers must be submitted electronically via the Defense Logistics Agency Internet Bid Board System (DIBBS).

• Offer Due Date: February 23, 2026, 3:00 PM EST.

• Evaluation Criteria: Lowest Price Technically Acceptable (LPTA). Award will be made to the responsible offeror whose proposal is technically acceptable and provides the lowest evaluated aggregate price.

• Proposals must include a Non-Price Proposal (Volume 1) and a Price Proposal (Volume 2).

• Offerors must complete representations and certifications electronically via SAM.gov.

• This acquisition is UNRESTRICTED.

• NAICS Code: 325412, Size Standard: 1300 employees.

• A reverse auction may be utilized for price discussions.

• Offerors must enter into business-to-business agreements with DLA and VA PPV contractors.

• The contract price may be adjusted by distribution fees, potentially resulting in a unit price lower than offered.